High-quality development contributes to the construction of a healthy China. Health Yuan won the title of "2022 China Economic Big Health High-quality Development Enterprise".

Time Posted：2022-12-20 22:11

The 2022 China Great Health Industry Summit Forum, hosted by the China Business Journal, concluded successfully on December 20, 2022. The "2022 Zhongjing Great Health Innovation and Development Exemplary Cases," a highlight of this year's forum, were announced. After rigorous selection by the judging committee, Health Spring Pharmaceutical Group was awarded the "2022 Zhongjing Great Health High-Quality Development Enterprise" title. Against the backdrop of unprecedented changes in a century and the intertwined impact of the epidemic, health has become a focal point of public concern. A better life is inseparable from high-quality medical and health services and guarantees, which also places higher demands on the development of the health industry. Guided by the Healthy China strategy, this forum, together with authoritative experts, scholars, entrepreneurs, and professional institutions, has in-depth analysis of the opportunities and challenges facing the development of China's great health industry. The cases in the forum focus on the four major fields of traditional Chinese medicine, biomedicine, digital medicine, and health management, seeking the most innovative and valuable benchmarks in the development of the great health industry and spreading the power of exemplary cases.

The Jiankangyuan product matrix demonstrates a magnitude-level breakthrough in market competition, with Jianketo becoming the world's first breakthrough product.

Time Posted：2022-12-20 22:09

On October 11, 2022, after eight years of development, tobramycin inhalation solution was finally approved for marketing and given the brand name Jianketo®. Behind this achievement lies a concentrated effort of new drug research and development, countless nights of hard work by researchers, and years of anticipation from patients. In 2014, academician Zhong Nanshan of the Chinese Academy of Engineering initiated a clinical research project on tobramycin inhalation solution. The reason for launching this project was the increasing incidence of bronchiectasis in China, coupled with a lack of clinical guidelines and relevant antimicrobial drugs. The fact that a leading figure in Chinese respiratory medicine places such importance on tobramycin highlights that this commonly used antibiotic is not so ordinary.

Good news! Lizhu Bio's recombinant COVID-19 fusion protein (CHO cell) vaccine has been included in the "Implementation Plan for the Second Booster Vaccination of COVID-19 Vaccines"

Time Posted：2022-12-15 01:18

On December 13, the Joint Prevention and Control Mechanism of the State Council's Leading Group on the Novel Coronavirus Pneumonia Epidemic issued the "Implementation Plan for the Second Booster Vaccination of COVID-19 Vaccines" (hereinafter referred to as the "Plan"), and the recombinant COVID-19 fusion protein (CHO cell) vaccine of Lizhu Biology was selected as a preferred combination.

Good news! Lizhu Bio's recombinant COVID-19 fusion protein (CHO cell) vaccine has been included in the "Implementation Plan for the Second Booster Vaccination of COVID-19 Vaccines"

Time Posted：2022-12-14 23:31

On December 13, the Joint Prevention and Control Mechanism of the State Council's Leading Group on the Novel Coronavirus Pneumonia Epidemic issued the "Implementation Plan for the Second Booster Vaccination of COVID-19 Vaccines" (hereinafter referred to as the "Plan"), and the recombinant COVID-19 fusion protein (CHO cell) vaccine of Lizhu Biology was selected as a preferred combination.

Exploring the History of New Drug Development: A New Book Sharing Session for "The Story of New Drugs 3" Successfully Held at HealthGen

Time Posted：2022-12-14 01:16

On December 13, 2023, HealthGen Biotech Group invited Dr. Liang Guibo, a renowned scientist in new drug research and development and the author of the popular science book series "The Story of New Drugs," to hold a new book sharing session at the group's headquarters in Shenzhen for his new book, "The Story of New Drugs 3." The sharing session was held both online and offline, attracting over 130 employees. Guests included Mr. Yu Xiong, President of HealthGen, and Dr. Jin Fang, Chief Scientist of HealthGen. "The Story of New Drugs 3" is the third installment in Dr. Liang Guibo's popular science series on Western medicine. Continuing the accessible style of the previous two books, it uses simple language and vivid descriptions to tell captivating stories from the forefront of life sciences, showcasing the progress and achievements of the human pharmaceutical industry. From psoriasis and diabetes to acromegaly and pulmonary fibrosis, from pathological research and drug development to clinical trials and market approval, Liang Guibo focuses on the years of exploration by laboratories, scientists, and pharmaceutical teams, leading readers to witness humanity's journey in battling diseases. At the event, author Liang Guibo shared the editing process and characteristics of the book. He guided readers to understand the ancient wisdom of our ancestors and the wonderful connection with modern medicine, focusing on widely-concerned health issues and telling exciting stories from the history of humanity's fight against diseases. He mentioned that the ancient wisdom and simple experiences passed down by our ancestors have nurtured and inspired modern medicine. For example, from hunting arrow poison in the American jungle to the real-world Shixiang Ruanjin Powder, and to the anesthetics widely used in surgery, modern science has repeatedly rediscovered the ancient wisdom of our ancestors, benefiting humanity time and again. At the same time, Liang Guibo also highlighted the years of exploration by laboratories, scientists, and pharmaceutical teams in their challenging journey to combat diseases. Liang Guibo graduated from the Department of Chemistry, Fudan University, majoring in organic chemistry. In the late 1980s, he went to the University of Wisconsin-Madison for further studies and obtained his doctorate. He conducted postdoctoral research at Cornell University. After graduation, Liang Guibo worked at Merck Laboratories for many years, making significant contributions to the development of sitagliptin. He has long been committed to the exchange and cooperation between the Chinese and American pharmaceutical industries and actively promotes the development of China's pharmaceutical and healthcare industry. Whether it's a major or minor illness, we interact with drugs throughout our lives. The history of humanity is also the history of drugs. Liang Guibo briefly reviewed the terrible viruses humanity has experienced in recent years and the contribution of pharmacology to global health. Ebola virus, SARS virus, and the current COVID-19 virus, under the background of global population movement, have inevitably spread exponentially, forming global epidemics. However, at any time, it is the collective wisdom of all mankind that is undergoing an unprecedented severe test. He stated that although COVID-19 vaccines cannot completely prevent viral infection, they can effectively prevent serious illness and death. The role of vaccination should not be underestimated, so he strongly recommends vaccination, such as the recombinant COVID-19 virus fusion protein (CHO cell) vaccine "Likang V-01" from HealthGen's subsidiary, Lizhu Bio. At the beginning of the COVID-19 pandemic, the country deployed five technological routes, including inactivated vaccines, adenovirus vector vaccines, recombinant protein vaccines, attenuated influenza virus vector vaccines, and nucleic acid vaccines, to ensure the success rate of COVID-19 vaccine research and development. "Likang V-01" is a research achievement under the new technological route of recombinant protein vaccines. In the face of the global COVID-19 pandemic, HealthGen, based on patient interests, adheres to innovation as its driving force, continuously focuses on China's major health industry, pays attention to investment in innovative technologies and the construction of R&D platforms, actively accelerates the research and development and global layout of innovative drugs and high-barrier complex preparations, and is committed to providing patients with more high-quality drug choices. Recently, HealthGen's new drug, Tobramycin Inhalation Solution Jianketo, "specially developed for Chinese patients," has been launched and put into clinical use. It is the first domestically produced nebulized inhaled antibiotic for the treatment of bronchiectasis in adults with Pseudomonas aeruginosa infection of the lungs, controlling infection and improving symptoms. The successful launch of Jianketo will change the situation where there are no available drugs in China for nebulized inhalation treatment of bronchiectasis, providing more support for bronchiectasis patients and improving their quality of life. Finally, in the interactive session, readers raised various questions about the content of the new book sharing, creating a strong professional and academic atmosphere. Liang Guibo answered each question one by one, engaging in thought-provoking discussions with the readers. This new book sharing session brought much encouragement and inspiration to HealthGen and its employees, and concluded successfully after the book signing and photo session. In the future, HealthGen will continue to uphold human life and health, adhere to its mission and vision of "For Health, For Tomorrow" and "Making Good Medicines with Heart," and actively and continuously contribute to building a community with a shared future for mankind.

Health Yuan plans to jointly establish a RMB 1 billion industrial investment joint venture company with Lizhu in Wuhan, increasing R&D investment.

Time Posted：2022-12-13 22:52

Recently, Healthy Yuan Pharmaceutical Group plans to jointly establish a joint venture company with its subsidiary, Lizhu Pharmaceutical Group, in Wuhan City. They will invest a total of 1 billion RMB to strategically invest in high-quality major health projects. This investment will help further increase the industrial innovation of the two groups, build a diversified platform for incubating and introducing high-quality R&D innovation projects, rapidly enrich the company's core pipeline products, and further enhance the group's sustained profitability.

Health Yuan Wins Cailian Press's 'Social Responsibility Pioneer Enterprise Award' for Deeply Implementing ESG Principles

Time Posted：2022-12-12 22:41

Recently, the "Diligence and Far-Reaching - 2022 Cailian Press Third ESG Enterprise Summit and 2022 Cailian Press 'Far-Reaching Award' Ceremony" was grandly held in Shanghai. Health Yuan, based on its outstanding performance in fulfilling social responsibilities, promoting industry development, and driving innovation, won the Cailian Press Far-Reaching Award for Socially Responsible Pioneer Enterprise.

Guiyang launches the first vaccination ceremony for the Omicron sequential vaccination of the elderly

Time Posted：2022-12-12 19:26

On December 12th, at 2:30 PM, the first sequential booster vaccination ceremony for the Zhuhai Lizhu recombinant novel coronavirus fusion protein vaccine was held in Guiyang. This vaccination activity was carried out to implement the overall requirements of the Guizhou Provincial Center for Disease Control and Prevention to accelerate the vaccination rate of people over 80 years old and continue to improve the vaccination rate of people aged 60-79, mobilizing social forces to participate in encouraging elderly people to receive sequential vaccinations of the COVID-19 vaccine. By "mixing and matching" COVID-19 vaccines produced using different biological technology routes, the aim is to achieve complementary advantages, compensate for the side effects of single vaccines, and effectively prevent the risk of Omicron infection among the elderly population.